Examkin

Soru

Zorluk: KolayMonitoring and Treatment Evaluation

During a routine follow-up evaluation, a primary care physician reviews the laboratory results of a patient who recently began antihypertensive therapy. The patient is a nulliparous female in her mid-fifties with uncomplicated type 2 diabetes mellitus. Three weeks prior, she was prescribed enalapril for blood pressure management. Today, she feels well and denies any dizziness, cough, or peripheral edema. Vital signs demonstrate a blood pressure of 132/84 mmHg132/84\text{ mmHg}, compared to a baseline of 154/92 mmHg154/92\text{ mmHg}.

Baseline laboratory studies (3 weeks ago):
Serum creatinine: 0.9 mg/dL0.9\text{ mg/dL}
Serum potassium: 4.2 mEq/L4.2\text{ mEq/L}

Current laboratory studies:
Serum creatinine: 1.1 mg/dL1.1\text{ mg/dL}
Serum potassium: 4.6 mEq/L4.6\text{ mEq/L}

Based on these findings, what is the most appropriate modification to this patient's treatment plan?

  1. Maintain the current medication regimen without changesCevap
  2. B
    Discontinue enalapril and initiate a calcium channel blocker
  3. C
    Reduce the enalapril dosage by fifty percent
  4. D
    Schedule bilateral renal artery ultrasonography
  5. E
    Add spironolactone to maximize renal protection

Cevap

The most appropriate approach is to maintain the current medication regimen without changes.
Angiotensin-converting enzyme (ACE) inhibitors lower systemic blood pressure and cause vasodilation of the efferent arterioles in the kidneys. This reduces intraglomerular pressure, which is ultimately protective against diabetic nephropathy, but causes a transient, expected decrease in the glomerular filtration rate (GFR). This manifests clinically as a mild rise in serum creatinine. A serum creatinine increase of up to 30% from baseline within the first 2 to 4 weeks of initiating an ACE inhibitor or angiotensin receptor blocker (ARB) is considered a normal, acceptable physiological response. Because this patient's creatinine increased by only ~22% and her potassium remains within normal limits, the medication should be continued without any dosage modifications.

Adım Adım Çözüm

1
Calculate the percentage change in the patient's serum creatinine.
Creatinine increased from 0.9 mg/dL to 1.1 mg/dL, which is an absolute increase of 0.2 mg/dL or roughly a 22% increase.
To determine whether the decline in renal function falls within the acceptable, expected range following ACE inhibitor initiation.
2
Evaluate the patient's potassium levels and clinical status.
Potassium is 4.6 mEq/L (within normal limits), blood pressure is well-controlled, and the patient is asymptomatic.
Hyperkalemia or symptomatic hypotension would be independent reasons to adjust or stop the medication.
3
Determine the next management step based on clinical guidelines.
Continue the current therapy.
An asymptomatic creatinine increase of less than 30% with normal potassium is a physiologic response to the drug's mechanism of action and warrants continuation of therapy.

Anahtar Kavram

Expected physiological changes in renal function following ACE inhibitor initiation
Bu soruyu puanla

Konular

Monitoring and Treatment Evaluation

Bu konudan daha fazla soru